Post by Terumo Pharmaceutical Solutions Division

4,561 followers

š—›š—¼š˜„ š—§š—²š—°š—µš—»š—¼š—¹š—¼š—“š˜† š—®š—»š—± š—¢š—½š—²š—æš—®š˜š—¶š—¼š—»š˜€ š—”š—æš—² š—¦š—µš—®š—½š—¶š—»š—“ š—–š——š— š—¢ š—–š—®š—½š—®š—Æš—¶š—¹š—¶š˜š—¶š—²š˜€: š—œš—»š˜€š—¶š—“š—µš˜š˜€ š—³š—æš—¼š—ŗ š—™š˜‚š—·š—¶š˜š—® š—”š—¼š—æš—¶š˜š˜€š˜‚š—“š˜‚ In the second instalment in our five-part interview series, Noritsugu Fujita discusses how Terumo's integrated CDMO capabilities, from formulation development and fill-finish services to device assembly and final packaging, help accelerate development timelines, reduce risk, and support scalability throughout the product lifecycle. šŸŽ¬ Watch the video to learn more. #TerumoPharmaceuticalSolutionsDivison #CDMO #LeadershipInsights #PharmaceuticalTechnology #Technology #Operations

Post content

Video Content